Norgine closes acquisition of Merus Labs International.

Norgine B.V. and Merus Labs International Inc. are pleased to announce the closing of the plan of arrangement under the Business Corporations Act (British Columbia) . Norgine and Merus previously announced the signing of the agreement in respect of the Arrangement in a press release issued on May 11, 2017 and the issuance of the final order of the Supreme Court of British Columbia in respect of the Arrangement in a press release issued on July 12, 2017. As a result of the transaction, Norgine acquires a product portfolio of 12 established products including SINTROM, EMSELEX, ELANTAN, ISOKET, DEPONIT, SALAGEN, and ESTRADERM which are sold across Europe and in other selected markets and VANCOCIN which is sold in Canada. The fiscal year 2016 sales of Merus� products were C$ 111.4 million. The acquisition strengthens Norgine�s position as a leading European specialist pharma company and continues its targeted business development focusing on specialist care products in a broad range of therapeutic areas. Merus, which has approximately 22 employees, becomes a wholly-owned subsidiary of Norgine.